Follow-up and Surveillance of Curatively Treated Lung Cancer Patients
The primary objective of this guideline is to develop recommendations for the optimal management of patients with lung cancer after curative-intent treatment.
The target population includes adult patients with small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) after curative-intent treatment.
Intended Guideline Users
This guideline is targeted to thoracic surgeons, medical and radiation oncologists specializing in lung cancer, radiologists, primary care providers, respirologists, nurses, and psychosocial care providers.
What are the benefits and harms of different types of clinicians providing follow-up care?
What are the benefits and harms of using patient-reported outcome tools or measures in providing follow-up care?
What are the benefits and harms of pneumococcal, influenza, and COVID-19 vaccinations?
What are the benefits and harms of smoking cessation interventions?
Which signs/symptoms/ risk factors/ comorbidities should be managed to improve their quality of life, risk of recurrence, survival, or risk of other primary cancers?
What are the late toxicities after any treatment (surgical, radiotherapy, chemotherapy, immunotherapy) that should be managed to improve their quality of life?
What are the benefits and harms of the treatment/ management strategies for signs/symptoms/risk factors/ comorbidities/ late toxicities?